Small Molecule for the Treatment of Equine Sepsis
Sepsis is a systemic inflammatory response to an infection and is responsible for nearly one-third of all foal mortality. Current treatment consists of broad-spectrum antibiotics, IV fluids, nutritional support, and administration of other medicines as the situation demands. Survival rates vary depending on the underlying cause of the disease and range from 26-86% for septic neonatal foals, with the majority of studies showing a rate of 45-60% 1,2.
The current invention, a small molecule that targets inflammation associated with Toll-like receptor overexpression, is able to protect horses from endotoxic shock.
Tech ID: 03007 View [PDF]
3 US Patent 9,326,972, issued May 3, 2016.
Photo of mare and foal obtained from Google Images.